Depo-Provera Lawsuit
- Last Updated: December 30th, 2024
Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.
Legally Reviewed
This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.
Fact-Checked
TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.
Depo-Provera Lawsuit [December 2024 Update & Overview]
Depo-Provera Lawsuit claims revolve around Depo-Provera, a popular injectable contraceptive manufactured by Pfizer Inc.
These Depo Provera Lawsuits allege that the Depo-Provera birth control shot increases the risk of developing brain tumors, specifically meningiomas.
On this page, we will discuss an overview of the Depo-Provera Lawsuit, new research linking Depo-Provera to brain tumors in women, who may qualify for the Depo-Provera Lawsuits, and much more.
Lawyers Are Currently Investigating Depo-Provera Lawsuits
Lawyers across the United States are actively investigating and accepting cases related to Depo-Provera use and subsequent brain tumor diagnoses.
These investigations are in the early stages, with attorneys gathering evidence and assessing potential claims.
Key points about the current state of Depo-Provera lawsuits include:
- Recent Scientific Evidence: The lawsuits are largely based on a March 2024 study published in the British Medical Journal (BMJ), which found that women injected with medroxyprogesterone acetate, the active ingredient in Depo-Provera, had a 5.6-fold higher risk of developing meningioma.
- Failure to Warn: The primary legal claim is that Pfizer failed to adequately warn users and healthcare providers about the potential risk of brain tumors associated with Depo-Provera use.
- Eligibility Criteria: Individuals who have used Depo-Provera or its generic form at least two (2) times and later developed a meningioma or another type of brain tumor may qualify to file a lawsuit.
- Early Stages: These cases are still in the early phases of litigation. No multidistrict litigation (MDL) has been formed, and there have been no settlements or jury verdicts yet.
- Potential for Consolidation: Given the widespread use of Depo-Provera, with approximately 24.5% of sexually active women having used it at some point (according to the CDC’s 2023 National Health Statistics Report), there is potential for these cases to be consolidated in federal court in the future.
As the litigation develops, more information about the scope and potential outcomes of these lawsuits is expected to emerge.
If you or a loved one has been diagnosed with a meningioma or another brain tumor potentially tied to Depo-Provera use, you may qualify to pursue legal action.
You can use the chat on this page to instantly determine if you may be eligible to file a Depo-Provera lawsuit.
Our team is available to answer any questions you may have about your potential claim and guide you through the next steps.
Table of Contents
Lawsuit Updates
-
December 2024 Updates:
December 27, 2024
Researchers at the University of Plymouth are spearheading a project to investigate meningiomas in NF2-related schwannomatosis (NF2-SWN), a condition caused by the loss of the NF2 gene.
Although meningiomas are generally non-cancerous, they can significantly impact patients’ quality of life.
Supported by the Children’s Tumor Foundation, the project focuses on developing a humanized model to study interactions between human immune cells and meningioma tumors.
This research is essential for advancing new therapies, particularly as meningiomas have shown resistance to chemotherapy.
While surgery is the primary treatment for most meningiomas, recurring or aggressive cases often require additional drug therapies, highlighting the need for improved treatment options.
Recent findings have also suggested a possible connection between Depo Provera, a hormonal contraceptive, and an increased risk of meningiomas.
Over 75 million women globally have reported using this drug.
Dr. Liyam Laraba leads the research at the University’s Brain Tumor Research Center of Excellence. Her team is working to create the humanized model by implanting human immune cells into mice, providing a more realistic approach to evaluating treatments prior to clinical trials.
This initiative is part of the Children’s Tumor Foundation’s NF Preclinical Hub Funding Program, aimed at expediting drug discovery and preclinical research for neurofibromatosis disorders.
Building on successful frameworks such as the NF Preclinical and Therapeutics Consortium, the program strives to accelerate the development of therapies for patients.
The project holds promise for delivering more effective treatments for meningiomas and improving outcomes for individuals with NF2-SWN.
If you or a loved one developed a brain tumor after using Depo-Provera, you may be eligible to seek compensation through a Depo-Provera Lawsuit.
Our team is currently accepting new clients.
Contact TruLaw’s Depo-Provera Lawyers for a free consultation or use the chatbot on this page to find out if you qualify for a claim instantly.
December 20, 2024
The Depo-Provera Lawsuit is ongoing.
A new lawsuit has been filed in the Eastern District of Louisiana against several pharmaceutical companies regarding the birth control drug Depo-Provera.
The plaintiff alleges that long-term use of Depo-Provera led to serious health conditions, including intracranial meningioma and paradoxical vocal cord dysfunction.
She began quarterly injections of Depo-Provera in 1992, shortly after the FDA approved the drug, and continued for three to four years.
In February 2020, she was diagnosed with intracranial meningioma, a condition linked to long-term use of Depo-Provera, as supported by numerous studies.
The lawsuit claims the defendants failed to warn her or her healthcare providers about the potential risks associated with extended use of the drug.
The plaintiff seeks compensatory damages for medical expenses, lost income, and other harm, as well as punitive damages for alleged negligence.
Currently, over 22 federal Depo-Provera lawsuits are pending across the United States, with the majority filed in California.
If you or a loved one developed a brain tumor after using Depo-Provera, you may be eligible to seek compensation through a Depo-Provera Lawsuit.
Our team is currently accepting new clients.
Contact TruLaw’s Depo-Provera Lawyers for a free consultation or use the chatbot on this page to find out if you qualify for a claim instantly.
December 27, 2024
Researchers at the University of Plymouth are spearheading a project to investigate meningiomas in NF2-related schwannomatosis (NF2-SWN), a condition caused by the loss of the NF2 gene.
Although meningiomas are generally non-cancerous, they can significantly impact patients’ quality of life.
Supported by the Children’s Tumor Foundation, the project focuses on developing a humanized model to study interactions between human immune cells and meningioma tumors.
This research is essential for advancing new therapies, particularly as meningiomas have shown resistance to chemotherapy.
While surgery is the primary treatment for most meningiomas, recurring or aggressive cases often require additional drug therapies, highlighting the need for improved treatment options.
Recent findings have also suggested a possible connection between Depo Provera, a hormonal contraceptive, and an increased risk of meningiomas.
Over 75 million women globally have reported using this drug.
Dr. Liyam Laraba leads the research at the University’s Brain Tumor Research Center of Excellence.
Her team is working to create the humanized model by implanting human immune cells into mice, providing a more realistic approach to evaluating treatments prior to clinical trials.
This initiative is part of the Children’s Tumor Foundation’s NF Preclinical Hub Funding Program, aimed at expediting drug discovery and preclinical research for neurofibromatosis disorders.
Building on successful frameworks such as the NF Preclinical and Therapeutics Consortium, the program strives to accelerate the development of therapies for patients.
The project holds promise for delivering more effective treatments for meningiomas and improving outcomes for individuals with NF2-SWN.
If you or a loved one developed a brain tumor after using Depo-Provera, you may be eligible to seek compensation through a Depo-Provera Lawsuit.
Our team is currently accepting new clients.
Contact TruLaw’s Depo-Provera Lawyers for a free consultation or use the chatbot on this page to find out if you qualify for a claim instantly.
December 13, 2024
Women who have used Depo-Provera, an injectable contraceptive produced by Pfizer, are pursuing legal action after experiencing severe side effects, including brain tumors.
Meningioma, a type of brain tumor that forms in the membranes surrounding the brain, can cause symptoms such as headaches, vision disturbances, and seizures.
The lawsuits allege that Pfizer failed to provide adequate warnings about the potential dangers of long-term Depo-Provera use.
Approved by the FDA in 1992 as a contraceptive, Depo-Provera contains medroxyprogesterone acetate, an ingredient used in other treatments since 1959.
The drug was promoted as a convenient birth control option, requiring only four injections annually, catering to individuals seeking reliable and low-maintenance contraception.
However, plaintiffs argue that this convenience came at the expense of unreported health risks.
A French study published in March 2024 found that using Depo-Provera for one year or more increased the risk of developing meningioma by 5.55 times.
The research analyzed data from over 18,000 women who underwent surgery for meningiomas between 2009 and 2018, supporting claims that prolonged Depo-Provera use significantly raises the risk of these tumors.
One plaintiff, referred to as T.C. for privacy reasons, stated she used Depo-Provera for three years and was later diagnosed with a meningioma.
During her use, she experienced prolonged bleeding, intense headaches, and severe fatigue.
After her diagnosis, T.C. underwent regular MRIs and treatments to monitor the tumor’s growth, which she describes as an ongoing source of anxiety.
Plaintiffs and their lawyers are advocating for increased awareness of the risks associated with Depo-Provera, urging women to consult medical professionals if they notice adverse symptoms and to consider legal action if a brain tumor develops.
If you or a loved one developed a brain tumor after using Depo-Provera, you may be eligible to seek compensation through a Depo-Provera Lawsuit.
Our team is currently accepting new clients.
Contact TruLaw’s Depo-Provera Lawyers for a free consultation or use the chatbot on this page to find out if you qualify for a claim instantly.
December 11th, 2024: California Woman Files Suit Over Depo-Provera-Related Brain Tumor
Another California resident has initiated legal proceedings in the U.S. District Court for the Eastern District of California, claiming that her use of Depo-Provera for approximately eight (8) years led to the development of an intracranial meningioma.
The lawsuit targets Pfizer, Inc., Pharmacia & Upjohn Co. LLC, and Pharmacia LLC — alleging strict liability, negligence, and breach of warranty.
The plaintiff contends that the defendants failed to provide adequate warnings about the risks associated with long-term use of Depo-Provera, particularly the potential for meningioma development.
Having used the contraceptive from 1994 to 2002, she was diagnosed with a meningioma in 2015 after experiencing severe neurological symptoms.
This case adds to the growing number of long-term usage claims and further solidifies California’s position as a focal point for Depo-Provera litigation, strengthening the argument for MDL consolidation in the state.
December 7th, 2024: Philadelphia Resident Files Depo-Provera Lawsuit in State Court
A new lawsuit has been filed in the Court of Common Pleas for Philadelphia County by a local resident, alleging that extended use of Depo-Provera resulted in the development of a debilitating meningioma.
The plaintiff, who began using the injectable contraceptive as a teenager, claims that the manufacturers (including Pfizer and affiliated companies) failed to adequately warn users about the risks associated with medroxyprogesterone acetate — the active ingredient in Depo-Provera.
The plaintiff, who has undergone multiple brain surgeries and continues to suffer from physical and cognitive impairments, is seeking both compensatory and punitive damages.
The lawsuit also names healthcare providers affiliated with the University of Pennsylvania Health System as defendants — alleging their failure to disclose safer contraceptive alternatives.
This case underscores the anticipated strong Depo-Provera docket in Philadelphia.
December 6th, 2024: Inoperable Brain Tumors Emerge as Significant Concern in Depo-Provera Cases
Legal representatives are observing a higher-than-expected incidence of inoperable meningiomas in Depo-Provera cases.
These tumors, which cannot be safely removed due to their location or involvement with critical brain structures, pose significant challenges for patients and medical professionals alike.
The impact of these inoperable tumors is profound, often resulting in persistent symptoms and ongoing health risks.
Patients frequently report severe headaches, vision loss, memory problems, and other neurological impairments.
Treatment options for these cases are limited, often restricted to radiation therapy or long-term monitoring, leaving patients to cope with both the physical and emotional toll of their condition.
December 5th, 2024: Depo Provera Cases Expected to Proceed as MDL, Not Class Action
Legal experts anticipate that lawsuits against Depo Provera manufacturers will likely be consolidated into a multidistrict litigation (MDL) rather than a traditional class action.
This approach, common in complex pharmaceutical cases, allows for efficient handling of numerous claims while preserving individual case integrity.
In an MDL, each plaintiff retains their own lawsuit, unlike a class action where one representative speaks for all.
Cases are transferred to a single federal court, where a judge oversees pre-trial proceedings, addressing common issues such as the alleged link between Depo Provera’s high-dose progestin and meningiomas, and the adequacy of warning labels.
The MDL structure offers benefits including individualized case consideration, streamlined pre-trial processes, and the option for either individual settlements or a global settlement agreement.
This approach is particularly suited to the Depo Provera situation, where injuries and circumstances vary significantly among plaintiffs.
December 4th, 2024: Proposed Depo-Provera Brain Tumor MDL Would Be Based in the United States District Court for the Northern District of California
Attorneys representing plaintiffs in Depo-Provera lawsuits have filed a motion to centralize all related cases into a federal multidistrict litigation (MDL).
The plaintiffs claim that Depo-Provera, a hormonal contraceptive containing medroxyprogesterone acetate, significantly increases the risk of developing brain tumors, with recent studies indicating a fivefold increase in risk for women using the product.
These lawsuits accuse the drug’s manufacturers of failing to adequately warn both users and the medical community about these potential dangers.
Many affected women have undergone invasive surgeries to treat their brain tumors and now face long-term consequences, including vision loss, seizure disorders, and lasting neurological damage.
On November 26, a motion was submitted to the U.S. Judicial Panel on Multidistrict Litigation (JPML), seeking to consolidate at least 22 lawsuits currently pending in eight district courts nationwide.
The proposed MDL would be based in the Northern District of California, where six of the cases are already filed.
Plaintiffs argue that centralization is necessary because the lawsuits share nearly identical allegations and legal questions, which would help streamline pretrial proceedings, prevent inconsistent rulings, and reduce legal expenses.
They also note that the litigation is expected to grow significantly, with additional claims anticipated in the coming months.
If the JPML grants the motion, all current and future Depo-Provera lawsuits will be assigned to a single judge for coordinated pretrial proceedings, including discovery and motions.
If you or a loved one developed a brain tumor after using Depo-Provera, you may be eligible to seek compensation through a Depo-Provera Lawsuit.
Our team is currently accepting new clients.
Contact TruLaw’s Depo-Provera Lawyers for a free consultation or use the chatbot on this page to find out if you qualify for a claim instantly.
December 2nd, 2024: 6 Manufacturers Named as Defendants in Proposed Depo-Provera Brain Tumor MDL
Legal representatives for twenty-two (22) women have initiated federal proceedings against six (6) manufacturers of Depo-Provera and its generic counterparts.
The motion for multidistrict litigation (MDL) consolidation identifies Pfizer, Pharmacia & Upjohn Co. LLC, Greenstone LLC, Viatris Inc., Pharmacia LLC, and Prasco LLC as defendants.
Should the consolidation occur, these entities could face liability for producing and marketing a contraceptive associated with brain tumor development in numerous women.
-
November 2024 Updates:
November 27th, 2024: Judicial Panel to Consider Consolidation of Depo-Provera Lawsuits into Multidistrict Litigation (MDL)
Plaintiffs in the Depo-Provera lawsuits have filed a motion with the Judicial Panel on Multidistrict Litigation (JPML) to consolidate the cases into a single multidistrict litigation (MDL).
With 22 cases currently pending, they have suggested the U.S. District Court for the Northern District of California as the venue, citing its track record with major MDLs, including Roundup.
The next hearing on the motion is set for December 5th, 2024 — meaning the JPML will not review this litigation until 2025.
If granted, it could become the first significant mass tort of the new year.
Plaintiffs argue that centralized pretrial proceedings through an MDL are critical to addressing the complexities of Depo-Provera lawsuits, which allege serious health issues (including meningiomas) that are linked to prolonged use of the contraceptive.
However, defendants are expected to oppose the motion and may propose transferring the cases to a District Court in New York.
Karen Caldwell, the panel chair, will preside over the hearing scheduled for early 2025, with multiple filings expected in the interim.
November 26th, 2024: Legal Grounds in the Depo-Provera Brain Tumor Lawsuit
The Depo-Provera litigation centers on allegations that Pfizer neglected to adequately disclose critical side effects on product labels and possessed knowledge of the contraceptive’s link to brain tumors.
Individuals diagnosed with brain tumors or meningiomas post-Depo-Provera use may be eligible for legal recourse.
TruLaw and other legal experts investigating the Depo Provera Lawsuit have evaluated over 7,000 related claims for this case.
TruLaw provides complimentary case assessments for those experiencing severe adverse effects.
You can use the chat on this page for an instant case evaluation to see if you may qualify for the Depo-Provera brain tumor lawsuit.
November 22nd, 2024: New Depo-Provera Lawsuits Name Healthcare Entities and Pharmacies
A recent lawsuit filed on November 15th, 2024, in the Superior Court of California in Alameda County, has named not only the manufacturers of Depo-Provera but also healthcare entities and pharmacies as defendants.
The plaintiff, Madison Le, alleges that these entities (including Kaiser Permanente International, Kaiser Foundation Health Plan Inc., and the Permanente Medical Group Inc.) were aware of the dangers associated with Depo-Provera through their own research but continued to administer and profit from the drug.
This lawsuit underscores the expanding scope of liability in Depo-Provera cases — highlighting the role of healthcare providers and pharmacies in the administration of the drug.
November 21st, 2024: Inoperable Brain Tumors Linked to Depo-Provera Use
Recent findings have highlighted that some brain tumors associated with Depo-Provera use are inoperable due to their location or infiltration into critical brain structures.
This means that affected women may require alternative treatments such as radiation therapy, hormone therapy, or participation in clinical trials — which can prolong their suffering and significantly impact their quality of life.
The inoperability of these tumors underscores the severe consequences of Depo-Provera use and the need for comprehensive preoperative imaging to assess treatment options.
November 20th, 2024: Las Vegas Woman Diagnosed with Multiple Brain Tumors After Long-Term Depo-Provera Use
A woman in Nevada has filed a lawsuit against Pfizer, alleging that her 20-year use of Depo-Provera led to the development of three intracranial meningiomas.
Tina Stephens-Smith experienced symptoms such as headaches, blurred vision, and speech problems before discovering the densely calcified tumors.
Her case highlights the long-term risks associated with Depo-Provera and the failure of Pfizer to adequately warn U.S. women about these dangers.
November 19th, 2024: Importance of Preoperative Imaging for Meningioma Patients
A review article in the Journal of Neuroimaging emphasizes the critical role of preoperative imaging in managing intracranial meningiomas linked to Depo-Provera use.
The article underscores the need for a strong foundation in the latest meningioma imaging techniques to optimize preoperative planning and improve patient outcomes.
This highlights the importance of targeted imaging for women who have used Depo-Provera and developed brain tumors that can be treated surgically.
November 15th, 2024: Study Finds 53% Increased Risk of Meningiomas After Depo-Provera Use
Lawsuits claim that Depo-Provera (a contraceptive medication manufactured by the defendants) caused significant harm, with scientific research linking the active ingredient in Depo-Provera, medroxyprogesterone acetate (MPA), to meningiomas.
A recent database analysis found that the injectable form of MPA raised the risk of developing meningiomas by 53%, with the risk increasing the longer the drug was used.
Additionally, data from 2004 to 2015 show a notable rise in meningioma cases, particularly among females, African Americans, and younger individuals.
Plaintiffs argue that the defendants were aware of this danger for decades but failed to warn U.S. patients and healthcare providers.
In contrast to the U.S., warnings about meningiomas have been added to the labels for Depo-Provera in Europe and Canada.
Depo-Provera’s known risks include:
- Bone Mineral Density Loss: Long-term use (over two years) may lead to permanent bone loss, especially in adolescents and high-risk individuals.
- Thrombosis: Discontinuation of the drug is recommended if thrombosis occurs, with further assessment required for any vision or neurological issues.
- Cancer Risks: Some users may experience an increased risk of breast and cervical cancers, particularly those with a family history of breast cancer.
- Ectopic Pregnancy: Severe abdominal pain or suspected pregnancy should prompt evaluation for an ectopic pregnancy.
- Adverse Reactions: Includes anaphylaxis, weight gain, depression, and irregular bleeding.
November 14th, 2024: Progesterone Study Strengthens Causation Claims in Depo-Provera Lawsuits
A study by David Bailey from January 2024 provides critical evidence for Depo-Provera lawsuits.
The study shows that stopping progesterone drugs like Depo-Provera can lead to the regression of meningioma size.
This finding supports both general and specific causation claims, bolstering the argument that Depo-Provera can cause an increased risk of meningioma and that it caused the meningioma in specific plaintiffs.
November 13th, 2024: Concerns Over Meningioma Risk Linked to Depo-Provera Continue to Grow
Concerns about the potential risk of developing brain tumors (particularly meningiomas) after using Depo-Provera continue to escalate.
Meningiomas are slow-growing tumors that can cause severe health issues due to increased pressure on brain tissue, nerves, and blood vessels.
As more evidence emerges about the link between Depo-Provera and brain tumors, legal actions against Pfizer for failing to appropriately update the contraceptive’s warning label are intensifying.
November 12th, 2024: Pfizer Includes Meningioma Warning for Canadian Patients But Not for U.S. Women
Pfizer has included a warning about the association between Depo-Provera and meningiomas in its product monograph for Canadian patients since at least 2016.
However, no such warning is included in the prescribing information for U.S. women.
This discrepancy has led to numerous lawsuits against Pfizer, alleging that the company failed to adequately warn U.S. women about the dangers of Depo-Provera.
November 9th, 2024: New Depo-Provera Lawsuit Filed in California Alleging Link to Meningioma
Mayra Valencia has filed a lawsuit in the Eastern District of California, alleging that her 23-year use of Depo-Provera led to the development of a brain tumor.
The complaint states that Pfizer knew or should have known about the risk of meningioma associated with Depo-Provera and failed to warn U.S. women.
The lawsuit also highlights studies dating back to 1983 that show a correlation between progesterone use and meningioma.
November 7th, 2024: Depo-Provera Settlement Amounts Could Be High Due to Several Factors
Depo-Provera settlement amounts are projected to be substantial due to several factors.
First, studies have shown a significant increase in the risk of brain tumors — with a 5.5x increased risk being one of the highest observed in mass torts.
Second, the type of injury (brain tumors) is particularly severe.
Additionally, Pfizer is well-funded and can afford significant settlements.
Given the relatively low number of potential lawsuits (estimated to be between 5,000 to 30,000), settlement values could be higher than in other mass torts — potentially exceeding $100,000 per case.
November 2nd, 2024: Depo-Provera Lawsuits Focus on Meningiomas and Potential Breast Cancer Link
Depo-Provera has been scrutinized for its potential health risks, including an increased risk of meningiomas and possibly breast cancer.
A 1988 study highlighted criticisms about the drug’s safety, including animal studies suggesting an increased cancer risk.
While current lawsuits primarily focus on meningiomas, there may also be a link to an increased risk of breast cancer for long-term users of Depo-Provera.
November 1st, 2024: Another Woman Files Depo-Provera Lawsuit Against Pfizer
A California woman, Anjanna Lawson, has filed a lawsuit against Pfizer and other defendants after being diagnosed with an intracranial meningioma.
Lawson started receiving Depo-Provera injections at age 16 and continued until September 2024.
Despite undergoing a right pterional craniotomy in July 2023 to remove the tumor, a residual tumor was discovered in early 2024, necessitating five sessions of stereotactic radiosurgery.
The tumor remains uneradicated, causing Lawson to suffer from vision loss, facial spasms, and a burning sensation in her face.
Her lawsuit seeks damages from Pfizer, Inc., Viatris, Inc., Greenstone, LLC, Prasco, LLC, Pharmacia & Upjohn LLC, and Pharmacia, LLC — alleging that these entities failed to adequately warn about the risks associated with Depo-Provera use.
Key notes regarding Anjanna Lawson’s Depo-Provera lawsuit:
- Plaintiff: Anjanna Lawson (a California resident).
- Defendants: Pfizer, Inc., Viatris, Inc., Greenstone, LLC, Prasco, LLC, Pharmacia & Upjohn LLC, and Pharmacia, LLC.
- Allegations: Failure to warn about the risks of developing intracranial meningiomas associated with Depo-Provera use.
- Symptoms: Vision loss, facial spasms, and a burning sensation in the face due to an uneradicated tumor.
- Treatment: Right pterional craniotomy and stereotactic radiosurgery.
- Lawsuit Focus: Seeking damages for the harm caused by Depo-Provera use.
If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit.
Our lawyers are still accepting new clients.
Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to find out if you qualify for a claim instantly.
-
October 2024 Updates:
October 30th, 2024: JPML Hearing Set for December 5th, 2024
The Depo-Provera lawsuit is ongoing.
Depo-Provera Lawsuits continue to be actively filed in federal courts, with projections suggesting over 30 cases could be filed by the end of November.
These filings are primarily concentrated in the Northern District of California and the Southern District of Texas.
A significant Judicial Panel on Multidistrict Litigation (JPML) hearing (to consider the potential for case consolidation into an MDL) is set for December 5th, 2024.
However, the formation of an official multidistrict litigation (MDL) is not expected before year-end.
An MDL typically forms when 25 or more related cases, addressing similar legal issues and involving the same defendants, are pending in various federal courts.
This threshold is anticipated to be met with the Depo-Provera cases.
While plaintiffs may prefer California as the coordination venue, defendants are expected to oppose this and suggest New York instead.
October 29th, 2024: New Depo-Provera Lawsuit Filed in California with Potential for Multidistrict Consolidation
The Depo-Provera lawsuit is ongoing.
A new case has been filed in the U.S. District Court for the Central District of California, accusing the makers of Depo-Provera of contributing to the development of a meningioma brain tumor in a woman who used the birth control shot for nearly 25 years.
The plaintiff is bringing legal action against Pfizer, Viatris, Greenstone, Prasco, and Pharmacia & Upjohn — claiming the companies did not provide adequate warnings in the U.S. regarding the risk of brain tumors (a warning that has been included on Canadian labels since 2015).
According to the lawsuit, the plaintiff began using Depo-Provera injections in 2000 and received a total of 91 doses over her treatment period.
In 2020, she started experiencing severe symptoms (including headaches, blurred vision, vertigo, and ear itching) — leading to the diagnosis of a calcified meningioma brain tumor that continued to grow.
Due to its calcified nature, surgical removal has been deemed too dangerous, leaving her with chronic pain and ongoing symptoms.
The complaint further alleges that Pfizer and related companies failed to adequately research and disclose the potential risks of long-term Depo-Provera use, which could include the development of meningiomas.
This case adds to the increasing number of Depo-Provera lawsuits being filed nationwide.
October 25th, 2024: Second Depo-Provera Lawsuit Filed Against Pfizer by Indiana Woman
An Indiana woman, Lesley Noble, has filed a lawsuit against Pfizer, alleging that her 20-year use of Depo-Provera caused her brain tumor and subsequent injuries.
Noble underwent invasive surgery to remove her intracranial meningioma in 2017, but the tumor aggressively regrew after six months.
She then underwent 36 rounds of radiation while still taking Depo-Provera, unaware of its potential causation.
Noble and her husband, Justin Noble, are demanding a jury trial for her injuries.
October 22nd, 2024: Pfizer and Co-Defendants Face 9 Accusations In First Depo-Provera Lawsuit
Pfizer and its co-defendants, including Viatris, Inc., Greenstone LLC, Prasco Labs, and Pharmacia & Upjohn, face nine allegations of wrongdoing in a federal Depo-Provera lawsuit filed by Kristina Schmidt in California.
The charges include Failure to Warn, Design Defect, Negligence, Negligent Failure to Warn, Negligent Design Defect, Negligent Misrepresentation, Fraudulent Misrepresentation, Breach of Express Warranty, and Breach of Implied Warranty.
These allegations accuse Pfizer and the other defendants of knowingly designing, marketing, and manufacturing a drug that could cause intracranial meningiomas without proper warning.
October 17th, 2024: Evidence Suggests Exposure to Hormones in Depo-Provera May Cause Spinal Tumors
Recent studies have linked Depo-Provera use to brain tumors, specifically intracranial meningiomas.
New research is focusing on meningiomas that form on the spinal cord.
An article in Neuro-Oncology Advances notes that while less than 13% of meningiomas are on the spinal cord, they make up about a quarter of spinal cord tumors.
The article suggests that external hormone sources, such as Depo-Provera injections, may be linked to a higher risk of developing meningiomas in the brain or spinal cord.
October 11th, 2024: Pfizer’s Legal Battle Over Depo-Provera and Generic Drug Liability
A central issue in the Depo-Provera lawsuit is whether Pfizer is legally responsible for meningiomas caused by generic versions of Depo-Provera.
The Supreme Court’s ruling in Mutual Pharmaceutical Co. v. Bartlett states that generic drug manufacturers are not liable if their drug has the same active ingredient as an approved drug.
However, in the Depo-Provera case, the generic manufacturers are mostly wholly owned subsidiaries of Pfizer, and the drugs were manufactured at the same sites as Depo-Provera.
This issue is expected to be aggressively litigated as part of the lawsuit.
October 10th, 2024: Statute of Limitations Considerations in Depo-Provera Lawsuits
The Depo-Provera lawsuits have highlighted important legal issues regarding the statute of limitations in such cases.
There are two (2) key factors that may allow individuals to file lawsuits for Depo-Provera-related injuries without being hindered by the statute of limitations:
- The “Discovery Rule”
- The Doctrine of Fraudulent Concealment
The first is the “Discovery Rule” — which is recognized in many states and allows the statute of limitations to be extended.
This rule delays the filing deadline until the injured party becomes aware of both the injury and its cause.
In the case of Depo-Provera, recent studies have uncovered a possible link between the drug and brain tumors, a connection that was not widely known before.
Because this evidence has only recently emerged, plaintiffs were not expected to know about the potential link between their conditions and Depo-Provera until now.
The second factor is the Doctrine of Fraudulent Concealment, which could also apply.
This legal doctrine allows the statute of limitations to be paused if the defendant deliberately hides key safety information.
Plaintiffs claim that Depo-Provera’s manufacturers concealed the drug’s risks by altering safety warnings and product labeling — making it difficult for consumers to identify the potential connection between Depo-Provera and brain tumors like meningiomas.
This alleged concealment means plaintiffs may argue they were unable to learn of the risks in time — effectively extending their window to file a lawsuit.
Together, the discovery rule and fraudulent concealment may provide a strong foundation for plaintiffs to challenge statute of limitations issues in the Depo-Provera lawsuits.
October 4th, 2024: Woman Files Lawsuit Against Pfizer Alleging Depo-Provera Caused Her Brain Tumor
Kristina Schmidt has filed a lawsuit against Pfizer in the Northern District of California, alleging that Depo-Provera caused her intracranial meningioma.
Her attorneys claim that Pfizer knew or should have known for decades that Depo-Provera could cause or substantially contribute to the development of meningiomas.
Since her diagnosis, Schmidt has endured significant, invasive treatments and experienced serious injuries.
This case is part of a growing number of lawsuits against Pfizer for their injectable contraceptive.
October 3rd, 2024: Depo-Provera Tied to Highest Cancer Rate Increase Among Commercial Drugs
Lawyers are highly interested in pursuing Depo-Provera lawsuits because early studies indicate that the drug makes the diagnosed injury over five times more likely to occur, one of the highest increases in cancer rates among commercially available drugs.
This contrasts with the Roundup lawsuit, where lawyers argued that Roundup causes a 69% increase in the likelihood of cancer — leading to several verdicts over $1 billion.
The proof in the Depo-Provera case is believed to be even stronger.
If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit.
Our lawyers are still accepting new clients.
Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to find out if you qualify for a claim instantly.
-
September 2024 Updates:
September 30th, 2024: Depo-Provera Lawsuit Expands as More Plaintiffs Learn of Potential Risks
The Depo-Provera lawsuit is gaining momentum as more potential plaintiffs become aware of the allegations against Pfizer.
A French study has established a link between Depo-Provera injections and meningiomas (tumors that arise from the protective membranes covering the brain and spinal cord).
Symptoms of meningioma may include (but are not limited to):
- Headaches
- Vision changes
- Seizures
- Memory loss
- Dizziness
Further research is needed to understand why Depo-Provera may increase the risk of tumor growth.
With 74 million women worldwide having used the drug, the potential scale of this litigation is significant.
September 25th, 2024: Depo-Provera’s Tumultuous History and Rising Legal Challenges
Depo-Provera’s journey has been marked by regulatory ups and downs since its development in 1959.
Initially approved by the FDA in 1974, the drug’s approval was revoked in 1978 due to cancer-related concerns.
It regained FDA approval in 1992 as a contraceptive.
Recent research (including a study published in the British Medical Journal) has uncovered a potential link between Depo-Provera use and the development of meningiomas and other brain tumors.
Given its widespread use over five decades, experts anticipate a significant increase in lawsuits in the coming years.
September 17th, 2024: Pfizer Confronts New Wave of Legal Action Over Depo-Provera
Pfizer is facing renewed legal scrutiny regarding Depo-Provera.
A recent study revealed that women who received as few as two Depo-Provera injections have a more than fivefold increased risk of developing meningiomas.
This isn’t the first time the drug has been at the center of legal disputes.
Previous lawsuits (such as the 2008 case Cassandra Colville v. Pharmacia & Upjohn) focused on allegations of bone density loss associated with the drug’s use.
Since then, Pfizer has acquired the rights to manufacture and distribute Depo-Provera.
September 13th, 2024: Study Reveals High-Value Potential of Meningioma Lawsuits Linked to Depo-Provera
A 2020 analysis of 47 meningioma lawsuits has caught the attention of legal professionals investigating cases involving women who used Depo-Provera.
The study found that in 68.1% of cases, failure to diagnose was the primary basis for legal action.
Notably, the average verdict in these lawsuits amounted to $3,409,650.22 — with settlements averaging $867,555.56.
These figures suggest that meningioma cases could result in substantial compensation.
If a causal link between Depo-Provera and increased meningioma risk is established, legal experts project settlement values could reach several hundred thousand dollars — considering Pfizer’s financial capacity.
September 10th, 2024: Potential Federal Consolidation of Depo-Provera Brain Tumor Claims
Approximately one-quarter of sexually active women have used Depo-Provera at some point in their lives.
As a result of its widespread use, numerous women diagnosed with brain tumors are now pursuing legal action against the drug’s manufacturers.
Legal experts anticipate that these cases will likely be consolidated in federal court — paving the way for coordinated legal proceedings against the pharmaceutical companies involved.
September 5th, 2024: Depo-Provera’s Complex Regulatory Past and Emerging Health Concerns
Depo-Provera faced multiple FDA rejections throughout the 1970s and 1980s before finally gaining approval in 1992.
Since its approval, the drug has been associated with reduced bone density and significant side effects upon discontinuation.
Originally developed by Upjohn, Depo-Provera is now manufactured by Pfizer.
Recent studies have further complicated the drug’s history by suggesting a potential link to brain tumors — adding to the existing health concerns surrounding its use.
If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit.
Our lawyers are still accepting new clients.
Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to find out if you qualify for a claim instantly.
Depo-Provera Lawsuit Investigation
Lawyers across the United States are actively investigating potential lawsuits against Pfizer, the manufacturer of Depo-Provera, due to the alleged link between the contraceptive injection and an increased risk of brain tumors, specifically meningiomas.
What Do the Depo Provera Lawsuits Claim?
The most recent Depo-Provera legal claims include various allegations against Pfizer.
The current Depo-Provera lawsuits primarily claim that:
- Pfizer failed to adequately warn Depo-Provera users and healthcare providers about the increased risk of developing brain tumors, particularly meningiomas, associated with long-term use of Depo-Provera.
- The company knew or should have known about these risks but did not conduct sufficient research or provide proper warnings.
- Patients suffered serious health complications, including brain tumors, as a result of using Depo-Provera without being fully informed of the risks.
- Pfizer may have been negligent in the design, testing, and marketing of Depo-Provera.
Previous Lawsuits Involving the Depo-Provera Birth Control Shot
The Depo-Provera birth control shot has faced multiple lawsuits over the years, with legal actions dating back to the early 2000s.
Previous lawsuits filed in relation to Depo-Provera injectable contraceptive shots include, but are not limited to:
- Bone Density Loss Claims: Earlier lawsuits focused on the drug’s link to significant bone mineral density loss. The lawsuits claimed that Pfizer did not sufficiently warn the public about the increased risk of osteoporosis and bone fractures.
- FDA Black Box Warning: In 2004, the FDA required Pfizer to include a “black box” warning on Depo-Provera’s label, indicating that extended use may lead to permanent and substantial loss of bone density.
- Canadian Class Action: In May 2008, a class action lawsuit was certified in Quebec against Pfizer concerning Depo-Provera, representing a nationwide class.
- Settlement: In 2021, Pfizer reached a settlement of over $2 million in a Canadian class action lawsuit concerning side effects related to bone density loss.
- Pseudotumor Cerebri Claims: Some lawsuits have also alleged that Depo-Provera could cause a condition called pseudotumor cerebri, which occurs when pressure builds up in the brain.
The new wave of lawsuits focusing on the link between Depo-Provera and brain tumors are still in the early stages, with no multidistrict litigation (MDL) formed yet and no settlements or jury verdicts reported.
If you believe you or a loved one may have developed a brain tumor or meningioma after using Depo-Provera birth control injections, we encourage you to reach out to TruLaw to discuss the specifics of your case.
You can use the chat on this page for an instant case evaluation to quickly see if you may qualify to file a Depo-Provera lawsuit.
Recent Developments in the Depo-Provera Litigation
Current Status of Lawsuits Filed
Currently, the Depo-Provera litigation is still in its early stages.
Lawyers across the United States are actively investigating and filing individual lawsuits on behalf of women who developed meningiomas or other brain tumors after using Depo-Provera.
These lawsuits are primarily being filed in state and federal courts against Pfizer, the manufacturer of Depo-Provera.
The number of lawsuits is expected to rise in the coming months as more women learn about the potential connection between Depo-Provera use and brain tumors.
Notable Court Rulings or Developments
While there have been no major court rulings specifically related to Depo-Provera brain tumor cases yet, a few notable developments have occurred:
- Scientific Evidence: The March 2024 study published in the British Medical Journal (BMJ) has become a cornerstone of these lawsuits. This study found that women injected with medroxyprogesterone acetate, the active ingredient in Depo-Provera, had a 5.6-fold higher risk of developing meningioma.
- Consolidation Efforts: Lawyers representing plaintiffs have begun discussions about potentially consolidating the cases for more efficient handling of pretrial proceedings.
- Pfizer’s Response: While Pfizer has not publicly commented on the specific allegations, the company maintains that Depo-Provera’s benefits outweigh its risks when used as directed.
Expectations for Potential Multidistrict Litigation (MDL)
In cases where numerous personal injury claims are filed over the same issue or product, the federal court system allows the consolidation of these cases into a multidistrict litigation (MDL).
If consolidation efforts for Depo-Provera Lawsuits are undertaken, it could mean a more systematic approach for victims to advocate for proper compensation.
An MDL would centralize all federal Depo-Provera lawsuits before a single judge for coordinated pretrial proceedings, including discovery and potential settlement negotiations.
Key points regarding a potential MDL include, but are not limited to:
- Timing: While no formal motion has been filed yet, legal experts expect a request for MDL formation to be submitted to the Judicial Panel on Multidistrict Litigation (JPML) within the next 6-12 months.
- Location: The location of a potential Depo-Provera MDL is yet to be determined, but it would likely be in a federal court where a large number of cases have been filed or where Pfizer has an established presence.
- Benefits: An MDL could streamline the litigation process, reduce costs for all parties involved, and potentially lead to faster resolutions through bellwether trials or global settlements.
- Challenges: Establishing general causation between Depo-Provera use and meningiomas may present a notable challenge in these cases, and the outcome of any scientific disputes could strongly impact the direction of the litigation.
As the Depo-Provera litigation continues to evolve, more developments are expected in the coming months.
Potential plaintiffs and their attorneys are closely monitoring the situation for any updates that could impact their cases.
If you or a loved one have used Depo-Provera birth control injections and subsequently developed a meningioma or other brain tumor, you may be eligible to seek compensation through a Depo Provera lawsuit.
To explore your options, reach out to us for more information by using the chat on this page for an instant case evaluation and quickly find out if you may qualify to file a Depo-Provera lawsuit.
Depo-Provera Injections Potentially Linked to Increased Risk of Cancer and Other Health Issues
What is the Depo-Provera Shot and How Does it Work?
Depo-Provera is an injectable birth control method that uses medroxyprogesterone acetate, a man-made version of the hormone progesterone.
The shot is typically administered every (12) weeks and works by:
- Preventing ovulation
- Thickening cervical mucus to block sperm
- Thinning the uterine lining to prevent implantation
Common Uses of Depo-Provera
Depo-Provera is prescribed to patients for a variety of use cases.
Of these use cases, Depo-Provera is most commonly used for:
- Contraception (birth control)
- Treatment of endometriosis-associated pain
- Management of abnormal uterine bleeding
What are the Problems and Side Effects Linked to Taking Depo Provera?
While Depo-Provera is an effective contraceptive, it has been associated with several side effects and potential health risks.
Side effects and potential health risks linked to Depo-Provera include, but are not limited to:
- Bone density loss
- Weight gain
- Irregular menstrual bleeding
- Headaches
- Mood changes
- Decreased libido
- Delayed return to fertility
- Possible increased risk of breast cancer
New Research Links Depo-Provera to Brain Tumors in Women
An important development in Depo-Provera research came from a March 2024 study published in the British Medical Journal (BMJ).
Key findings include:
- Women using medroxyprogesterone acetate (Depo-Provera) for more than a year had a 5.6-fold higher risk of developing intracranial meningioma.
- The study examined data from 18,061 women who had surgery for meningioma between 2009 and 2018.
- Although 92.3% of these meningiomas were benign, they can still lead to serious complications by impacting surrounding brain tissue, nerves, and blood vessels.
- Two additional progestogen-based medications, medrogestone and promegestone, were likewise linked to a higher risk of meningioma, with increases of 4.1-fold and 2.7-fold, respectively.
- The authors determined that extended use of medrogestone, medroxyprogesterone acetate, and promegestone raised the risk of developing intracranial meningioma.
In response to these findings, Pfizer, the manufacturer of Depo-Provera, is working with regulatory authorities to update product labels and patient information regarding this potential risk.
This recent research has led law firms to begin accepting cases from women who repeatedly used Depo-Provera and subsequently developed meningiomas.
It’s important to note that while this study shows a correlation, it does not definitively prove causation.
If you or a loved one has been diagnosed with a brain tumor or meningioma after using Depo-Provera birth control injections, you may be eligible to file a claim for compensation.
We encourage you to reach out to us with any questions about your potential case.
Our team is here to guide you through the process — you can use the chat on this page for an instant case evaluation to quickly determine if you qualify to file a Depo-Provera lawsuit.
Do You Qualify for the Depo-Provera Shot Lawsuit?
To determine if you qualify for a Depo-Provera lawsuit, you must meet specific criteria related to your use of the birth control medication and subsequent health issues.
Eligibility Criteria in the Depo-Provera Lawsuit
To qualify for a Depo-Provera lawsuit, potential claimants must meet specific requirements that establish a connection between their use of the medication and their health condition.
To be eligible for a Depo-Provera lawsuit, you generally must meet the following criteria:
- Depo-Provera Usage: You must have used brand-name Depo-Provera, Depo-SubQ Provera 104, or an authorized generic version of medroxyprogesterone acetate.
- Frequency: You must have received at least two injections of Depo-Provera or its authorized generic version.
- Timing: You must have used Depo-Provera or its authorized generic version any time after 1992.
- Diagnosis: You must have been diagnosed with a meningioma or another type of brain tumor after using Depo-Provera.
- Causation: The brain tumor diagnosis must have occurred after starting Depo-Provera use.
It’s worth noting that individuals who used Depo-Provera for extended periods might have stronger legal claims compared to those who used it only a handful of times.
The criteria above is strictly intended to give you an idea of factors that may be weighed when determining your eligibility for a Depo-Provera lawsuit — this should not be taken as a guarantee that you will qualify to file a claim or as legal advice.
Depo-Provera Lawsuit Statute of Limitations and Deadlines
To ensure your right to file a lawsuit is preserved, it’s important to seek legal advice as soon as you notice any side effects that could potentially be linked to your usage of Depo-Provera.
The statute of limitations for filing a Depo-Provera lawsuit differs by state and can greatly affect your ability to pursue legal action:
- Time Limits: Depending on your state, the statute of limitations could be as short as two (2) years from when the side effects of Depo-Provera became noticeable or reasonably should have been noticed.
- Discovery Rule: In some states, the statute of limitations may begin when you discovered or reasonably should have discovered the link between Depo-Provera and your brain tumor.
- Urgency: It’s important to contact an attorney promptly after a diagnosis to ensure you don’t miss the deadline for filing a claim.
- State Variations: The specific time limit can vary widely from state to state, so it’s important to consult with a lawyer who is knowledgeable about the laws in your jurisdiction.
- Exceptions: Some states may have exceptions that extend the statute of limitations under certain circumstances, such as for minors or in cases of fraudulent concealment.
Given the detailed nature of these time limits and the potential for variations based on individual circumstances, it’s strongly advised to consult with an experienced Depo-Provera lawsuit attorney as soon as possible.
The product liability attorneys at TruLaw and our partner law firms are investigating the potential for a Depo-Provera lawsuit, and are here to help you understand your legal rights if you’ve developed a brain tumor or meningioma after using Depo-Provera birth control injections.
As we’re investigating this lawsuit, TruLaw can help you determine potential deadlines that may apply to your case and ensure that your rights are protected.
You can use the chat on this page to connect with our team and instantly determine if you may be eligible to file a Depo-Provera lawsuit.
Process for Filing a Depo-Provera Lawsuit
Pursuing a Depo-Provera lawsuit involves carefully following several key steps — this can help ensure your case is strong and increase your chances of a successful claim.
Hire an Experienced Product Liability Lawyer
The first and most important step in filing a Depo-Provera lawsuit is to hire an experienced product liability lawyer.
Here’s why this is important:
- Expertise: Product liability cases, particularly those involving pharmaceuticals, can be challenging. An experienced lawyer will be familiar with the details and subtleties of these cases.
- Resources: Established law firms have the resources to thoroughly investigate your claim and build a strong case.
- Negotiation Skills: Your lawyer will be able to negotiate effectively with Pfizer’s legal team.
- No Upfront Costs: Most product liability lawyers work on a contingency fee basis, meaning you don’t pay unless you win your case.
Collect the Necessary Evidence to File a Depo-Provera Lawsuit
Gathering thorough evidence is extremely important for building a strong case.
Your lawyer will help you gather evidence, such as:
- Medical Records: Documentation of your Depo-Provera use, including prescription records and doctor’s notes.
- Diagnosis Records: Proof of your meningioma or brain tumor diagnosis, including pathology reports and imaging results.
- Treatment Records: Documentation of all treatments received for your condition.
- Pharmacy Records: Detailed records showing the dispensing of Depo-Provera, establishing the timeline and frequency of use.
- Personal Testimony: Your account of Depo-Provera use, onset of symptoms, and the impact on your life.
- Witness Statements: Testimonies from family or friends corroborating the impact on your life.
- Financial Records: Documentation of economic losses due to medical bills and lost wages.
Assess Recoverable Damages in the Depo-Provera Lawsuit
Your lawyer will help you assess the potential damages you can recover.
These may include, but are not limited to:
- Medical Expenses: Costs for diagnosis, treatment, and ongoing care.
- Lost Wages: Compensation for time missed from work.
- Pain and Suffering: Damages for physical pain and emotional distress.
- Loss of Quality of Life: Compensation for the impact on your daily activities and enjoyment of life.
- Punitive Damages: In some cases, additional damages may be awarded to punish the defendant and deter similar conduct.
File Your Depo-Provera Lawsuit
Your lawyer will take all the necessary steps to ensure your case is properly presented in court.
Once all evidence is gathered and damages are assessed, your lawyer will file the lawsuit:
- Drafting the Complaint: Your lawyer will prepare a legal document detailing your allegations against Pfizer.
- Filing in the Appropriate Court: The lawsuit will be filed in the court with proper jurisdiction.
- Serving the Defendant: Pfizer will be officially notified of the lawsuit.
- Potential MDL: Your case may be consolidated with others in a Multidistrict Litigation (MDL) for more efficient handling.
Your lawyer will guide you through each step, keeping you informed and advocating for your rights throughout the process.
If you believe you have a case, it’s important to act quickly, as there are time limits (statutes of limitations) for filing such lawsuits.
You can use the chat on this page to connect with our team and instantly determine if you may be eligible to file a Depo-Provera lawsuit.
Depo-Provera Brain Tumor Lawsuit Settlement and Payout Amounts
When it comes to estimating potential settlement amounts for Depo-Provera brain tumor lawsuits, it’s important to recognize that this litigation is still in the very early stages.
As a result, any projections about possible compensation remain uncertain at this time.
We still need to determine whether the scientific evidence linking Depo-Provera to brain tumors will be considered admissible in court.
However, we can make an educated guess based on similar tort cases that involve comparable injuries and facts.
It’s important to note that the projections discussed below are strictly to give affected individuals a general idea of what these settlement values could end up looking like if claims are successful — as the litigation progresses, more accurate estimates may become possible.
Depo-Provera Lawsuit Settlement Predictions
If the causation evidence stands up in court, lawyers believe that successful Depo-Provera brain tumor cases involving significant complications could potentially have a settlement value ranging from $100,000 to $500,000.
These estimates should not be taken as a guarantee and actual settlement amounts in successful Depo-Provera claims may vary substantially based on a wide variety of factors.
This wide range reflects the different degrees of severity associated with meningiomas.
The symptoms, treatment options, and long-term prognosis for different forms of meningioma can vary greatly based on the grade of meningioma:
Grade I Meningiomas (Non-Cancerous)
Grade I meningiomas are generally less serious and not life-threatening:
- Classification: Benign meningiomas
- Rarity: Account for roughly 78-81% of all meningiomas.
- Aggressiveness: Grade I meningiomas are the least aggressive type, growing slowly with distinct borders.
- Growth Rate: They tend to grow at a very slow rate compared to higher-grade meningiomas.
- Invasiveness: Grade I meningiomas typically do not invade surrounding brain tissue.
- Treatment: Surgery may not be required unless the tumor is causing symptoms or discomfort.
Grade III Meningiomas (Cancerous)
Grade III meningiomas are much more dangerous and could be life-threatening:
- Classification: Anaplastic or malignant meningiomas
- Rarity: They are relatively rare, accounting for only about 1-4% of all meningiomas.
- Aggressiveness: Grade III meningiomas are the most aggressive and fastest-growing type of meningioma.
- Growth Rate: They grow and spread quickly compared to lower-grade meningiomas.
- Invasiveness: These tumors tend to invade surrounding brain tissue and have a high likelihood of recurring after treatment.
- Treatment: Due to their aggressive nature, Grade III meningiomas typically require more intensive treatment, often involving a combination of surgery and radiation therapy.
Other Factors
Other factors that may influence settlement amounts include, but are not limited to:
- Duration of Depo-Provera use
- Age of the plaintiff
- Impact on quality of life and ability to work
- Strength of evidence linking Depo-Provera to the tumor
It’s still too early to predict how many cases will fall into each of these categories, but some attorneys expect that Depo-Provera cases involving Grade III meningiomas could lead to substantial compensation.
If these cases go to trial, some settlements could reach millions of dollars.
While a global settlement might not result in average payouts at this level, it’s possible that some individual cases could settle for over $1 million, depending on how this litigation unfolds.
Another factor to consider is that Pfizer, the manufacturer of Depo-Provera, is a company valued at over $150 billion.
With its recent profits, Pfizer has the financial resources to support substantial settlements if necessary.
Unlike some other mass tort cases where a defendant’s ability to pay is a concern, this isn’t an issue in the Depo-Provera litigation.
Comparison to Similar Litigations
Previous settlements in cases with comparable injuries can also help provide a benchmark for potential outcomes in Depo-Provera litigation.
To provide context, we can look at settlements in other pharmaceutical cases involving similar injuries:
- In 2021, Bayer agreed to pay $1.6 billion to settle thousands of claims related to its Essure birth control device, which averages to about $45,600 per plaintiff.
- In 2012, Bayer agreed to settle thousands of U.S. lawsuits related to its Yaz and Yasmin birth control pills, which alleged the company downplayed the risks of blood clots. By late 2023, Bayer had reached settlements totaling over $850 million for thousands of Yasmin and Yaz lawsuits linked to injuries like deep vein thrombosis (DVT) and pulmonary embolism — experts estimate that Bayer may need an additional $2.6 billion to resolve the remaining cases.
- In 2017, Bayer agreed to pay $12.2 million to settle approximately 4,600 cases related to its Mirena IUD, specifically for organ perforation and device migration.
- The average payout in transvaginal mesh lawsuits has ranged from $40,000 to $450,000 per case.
Timeline for Settlements
Given the early stage of the litigation, it may be several years before any settlements are reached.
Typically, pharmaceutical mass tort cases follow this general timeline:
- Notice of public issue
- Lawyers investigate allegations being made in claims
- Initial lawsuits are filed
- Cases consolidated into multidistrict litigation (MDL)
- Discovery phase and pretrial proceedings
- Bellwether trials to test the strength of claims
- Global settlement negotiations
You can use the chat on this page to discuss the specifics of your case with our team and instantly determine if you may be eligible to file a Depo-Provera lawsuit.
TruLaw is Actively Evaluating Claims for the Depo-Provera Lawsuit
TruLaw is actively investigating potential Depo-Provera lawsuits for women who have developed brain tumors following the use of this contraceptive injection.
As the litigation is still in its early stages, the experienced product liability attorneys at TruLaw and our partner law firms are working to gather evidence, review medical records, and monitor the latest scientific studies that link Depo-Provera to an increased risk of meningiomas.
If you or a loved one has been diagnosed with a meningioma or brain tumor after using Depo-Provera, we encourage you to reach out to TruLaw for a free, no-obligation case evaluation.
You can do so by using the chat on this page for an instant case evaluation to quickly see if you may qualify to file a Depo-Provera lawsuit.
Our experienced team is ready to review your case, explain your legal options, and fight for the compensation you deserve.
As this litigation evolves, TruLaw will continue to provide updates and support to those affected by Depo-Provera’s potential side effects.
We remain dedicated to seeking justice for our clients and ensuring that pharmaceutical companies prioritize patient safety over profits.
Frequently Asked Questions
-
Who is the manufacturer of Depo Provera?
Pfizer Inc. is the current manufacturer of Depo-Provera, a popular long-acting reversible contraceptive (LARC).
The drug was initially developed by Upjohn, a pharmaceutical company that eventually merged with Pharmacia and was subsequently acquired by Pfizer in 2003.
-
Have Depo-Provera products been proven to be dangerous?
While Depo-Provera is FDA-approved, it has been associated with some serious side effects.
Studies have linked its use to bone density loss and an increased risk of meningioma brain tumors.
To address these concerns, the FDA added a black box warning about bone density loss in 2004.
-
Has Pfizer issued any warnings or recalls related to Depo-Provera and brain tumors?
Pfizer has not issued any specific recalls related to brain tumors in Depo-Provera.
However, at the FDA’s request, the company added a black box warning to the drug’s label in 2004 to highlight the potential risk of bone density loss with prolonged use.
-
What are the exclusions or disqualifying factors that might prevent me from filing a Depo-Provera lawsuit?
Several factors could disqualify you from filing a Depo-Provera lawsuit.
These include, but are not limited to:
- Not using brand-name Depo-Provera: Generic alternatives might not be included in legal actions.
- Using it fewer than two times: Limited exposure might not be sufficient.
- Using it before 1992: The drug’s formulation changed in 1992, which could affect legal claims.
- Not being diagnosed with meningioma: The lawsuit is specifically related to this type of brain tumor.
- Falling outside your state’s statute of limitations: There are time limits for filing legal claims.
-
What are the Serious Side Effects of Depo Provera Injections?
Depo-Provera can have serious side effects, including but not limited to:
- Bone density loss: Long-term use can lead to weakened bones.
- Increased risk of meningioma brain tumors: Studies have linked Depo-Provera to a higher risk of this type of tumor.
- Blood clots: There’s a slightly increased risk of blood clots, especially in the legs and lungs.
- Liver problems: In rare cases, Depo-Provera can cause liver damage.
- Ectopic pregnancy: While rare, there’s a slightly increased risk of ectopic pregnancy if conception occurs while using Depo-Provera.
- Severe allergic reactions: Some individuals may experience severe allergic reactions to the medication.
-
What are the Minor Side Effects of Depo Provera?
Depo-Provera can cause many common minor side effects, including but not limited to:
- Irregular menstrual bleeding: This is a common side effect, especially during the first few months of use.
- Weight gain: Certain individuals might notice an increase in weight.
- Headaches: Headaches can occur in some users.
- Mood changes: Mood swings or changes in emotional state are possible.
- Decreased sex drive: A lower sex drive is a potential side effect.
- Breast tenderness: Breast sensitivity or tenderness may occur.
These minor side effects often improve over time as the body adjusts to the hormone.
If you experience any side effects that are bothersome or persist, it’s important to consult with your healthcare provider.
-
How Many Women Receive the Depo Shot Regularly?
Approximately 2 million women in the United States regularly receive the Depo-Provera shot.
This makes it a popular long-acting reversible contraceptive (LARC) option.
Globally, injectable contraceptives (including Depo-Provera and other options) are used by around 74 million women.
-
What are the Different Types of Depo Provera Shots?
There are two (2) primary types of Depo-Provera:
- Traditional Depo-Provera (150 mg): This is an intramuscular injection administered every 12-14 weeks.
- Depo-subQ Provera 104 (104 mg): This is a lower-dose subcutaneous injection, also administered every 12-14 weeks.
Both options offer effective birth control but may have different side effect profiles.
-
How Does the Depo Provera Birth Control Shot Work?
Depo-Provera works by releasing the hormone progestin, which prevents pregnancy in three (3) ways:
- Suppresses ovulation: This means the ovaries don’t release an egg each month.
- Thickens cervical mucus: This creates a barrier that blocks sperm from reaching the egg.
- Thins the uterine lining: This makes it less likely for a fertilized egg to implant in the uterus.
-
Is there a Depo-Provera Class Action Lawsuit?
While there is currently no active Depo-Provera class action lawsuit specifically for brain tumor claims, individual lawsuits are being filed.
Women who have developed meningiomas after using Depo-Provera are pursuing legal action.
These cases are currently in their early stages, and attorneys are investigating potential claims.
There’s a possibility that these individual cases may be consolidated into a multidistrict litigation (MDL) in the future, but this has not occurred yet.
-
What are the primary legal claims in the Depo-Provera brain tumor lawsuits?
The primary legal claims in Depo-Provera brain tumor lawsuits are failure to warn and product liability.
Plaintiffs allege that Pfizer, the manufacturer, failed to adequately inform users and healthcare providers about the increased risk of developing meningiomas (brain tumors) associated with prolonged use of Depo-Provera.
These claims suggest that Pfizer knew or should have known about the risk but failed to take appropriate measures to protect consumers.
-
Are there any studies linking Depo-Provera to brain tumors?
Yes, there is a study linking Depo-Provera to brain tumors.
A March 2024 study published in the British Medical Journal (BMJ) found a significant association between long-term use of medroxyprogesterone acetate (the active ingredient in Depo-Provera) and an increased risk of developing intracranial meningioma.
This study analyzed data from over 18,000 women who underwent surgery for meningioma.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
You can learn more about the Depo-Provera Lawsuit by visiting any of our pages listed below:
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
AFFF Lawsuit claims are being filed against manufacturers of aqueous film-forming foam (AFFF), commonly used in firefighting.
Claims allege that companies such as 3M, DuPont, and Tyco Fire Products failed to adequately warn users about the potential dangers of AFFF exposure — including increased risks of various cancers and diseases.
Suboxone Tooth Decay Lawsuit claims are being filed against Indivior, the manufacturer of Suboxone, a medication used to treat opioid addiction.
Claims allege that Indivior failed to adequately warn users about the potential dangers of severe tooth decay and dental injuries associated with Suboxone’s sublingual film version.
Social Media Harm Lawsuits are being filed against social media companies for allegedly causing mental health issues in children and teens.
Claims allege that companies like Meta, Google, ByteDance, and Snap designed addictive platforms that led to anxiety, depression, and other mental health issues without adequately warning users or parents.
Transvaginal Mesh Lawsuits are being filed against manufacturers of transvaginal mesh products used to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI).
Claims allege that companies like Ethicon, C.R. Bard, and Boston Scientific failed to adequately warn about potential dangers — including erosion, pain, and infection.
Bair Hugger Warming Blanket Lawsuits involve claims against 3M — alleging their surgical warming blankets caused severe infections and complications (particularly in hip and knee replacement surgeries).
Plaintiffs claim 3M failed to warn about potential risks — despite knowing about increased risk of deep joint infections since 2011.
Baby Formula NEC Lawsuit claims are being filed against manufacturers of cow’s milk-based baby formula products.
Claims allege that companies like Abbott Laboratories (Similac) and Mead Johnson & Company (Enfamil) failed to warn about the increased risk of necrotizing enterocolitis (NEC) in premature infants.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
